1. Home
  2. ATCH vs HBIO Comparison

ATCH vs HBIO Comparison

Compare ATCH & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AtlasClear Holdings Inc.

ATCH

AtlasClear Holdings Inc.

HOLD

Current Price

$0.19

Market Cap

28.7M

Sector

N/A

ML Signal

HOLD

Logo Harvard Bioscience Inc.

HBIO

Harvard Bioscience Inc.

HOLD

Current Price

$8.02

Market Cap

26.5M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATCH
HBIO
Founded
2022
1901
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
28.7M
26.5M
IPO Year
2024
2000

Fundamental Metrics

Financial Performance
Metric
ATCH
HBIO
Price
$0.19
$8.02
Analyst Decision
Strong Buy
Buy
Analyst Count
1
2
Target Price
$1.00
$18.00
AVG Volume (30 Days)
1.1M
15.6K
Earning Date
05-15-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.05
N/A
Revenue
N/A
$116,176,000.00
Revenue This Year
$84.47
$4.77
Revenue Next Year
$39.32
$8.55
P/E Ratio
$3.92
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.17
$0.38
52 Week High
$0.86
$8.40

Technical Indicators

Market Signals
Indicator
ATCH
HBIO
Relative Strength Index (RSI) 55.27 63.00
Support Level $0.19 $5.91
Resistance Level $0.21 $8.40
Average True Range (ATR) 0.01 0.26
MACD 0.00 -0.06
Stochastic Oscillator 73.67 29.09

Price Performance

Historical Comparison
ATCH
HBIO

About ATCH AtlasClear Holdings Inc.

AtlasClear Holdings Inc is a fintech company. Its goal is to build a cutting-edge technology-enabled financial services firm that would create a more efficient platform for trading, clearing, settlement, and banking of evolving and financial products with a focus on financial services firms. It is a fintech-driven business-to-business platform that expects to power innovation in fintech, investing, and trading. The company believes it is positioned to provide a modern, mission-critical suite of solutions to its clients, enabling them to reduce their transaction costs and compete more effectively in their businesses.

About HBIO Harvard Bioscience Inc.

Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.

Share on Social Networks: